An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Официальное название

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy

Обзор

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

Подробное описание

This study aims to characterize the pharmacokinetics, pharmacodynamics, efficacy, and safety of anifrolumab solution for infusion compared with placebo solution for infusion in pediatric participants with severe active systemic lupus erythematosus who are on background standard of care therapy.

The study duration for a participant will be approximately 116 weeks, which includes:

* Screening period of up to 30 days. * Part A consists of a four-week, double-blind, placebo-controlled, randomised, pharmacokinetic period. * Part B is a double-blind, placebo-controlled, randomised, safety/efficacy period lasting 48 weeks (for rollover participants from Part A) or 52 weeks (for de novo participants). * Part C is a 52-week open-label extension period. * Part D is a safety follow-up period. One safety visit at 12 weeks post last dose.

Вмешательства

• Биопрепарат Anifrolumab
  Participants will receive anifrolumab via IV infusion.
• Препарат Placebo
  Participants will receive matching placebo via IV infusion

Первичные конечные точки

• Part A- Anifrolumab serum concentration [Срок оценки: Pre-dose Day 29]
• Part A - Maximum observed serum (peak) drug concentration (Cmax) [Срок оценки: Up to Day 29]
• Part A - Area under the serum concentration curve (AUC) [Срок оценки: Up to Day 29]
• Part A - Minimum observed serum concentration (Cmin) [Срок оценки: Up to Day 29]
• Part B - Number of participants who are British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responders (yes/no) [Срок оценки: At Week 52]

Вторичные конечные точки (11)

• Part B - Number of participants who are Systemic Lupus Erythematosus Responder Index of ≥ 4 SRI(4) responders (yes/no) [Срок оценки: At Week 52]
• Part B - Time to first flare [Срок оценки: Through Week 52]
• Part B - Anifrolumab serum concentration [Срок оценки: Pre-dose Week 12, Pre-dose Week 24, Pre-dose Week 52]
• Part - B Change from baseline through Week 52 in antidrug antibody (ADA) [Срок оценки: Up to Week 52]
• Part - B Change from baseline in anti-double stranded deoxyribonucleic acid antibodies [Срок оценки: At Week 12 and Week 52]
• Part - B Change from baseline in total hemolytic complement (CH50) [Срок оценки: At Week 12 and Week 52]
• Part - B Change from baseline in complement component (C3) [Срок оценки: At Week 12 and Week 52]
• Part - B Change from baseline in complement component (C4) [Срок оценки: At Week 12 and Week 52]
• Number of participants who are Pediatric Rheumatology International Trials Organization/American College of Rheumatology (PRINTO/ACR) childhood-onset systemic lupus erythematosus (cSLE) responders (yes/no) [Срок оценки: At Week 52]
• Part B - The mean percentage reduction from Baseline through Week 52 in oral corticosteroid(s) (OCS) background dose [Срок оценки: At Week 52]
• Part B - Change from baseline through Week 52 in type I interferon (IFN) 21-gene signature [Срок оценки: At Week 52]

Критерии участия

Критерии включения

• Participant's parent/caregiver/legally authorized representative and participant (if required per local country regulation) capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Informed assent is to be provided by the participant per local country regulation.
• Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) criteria for at least 3 months prior to signing the ICF.
• At Screening, participant must have moderate to severe active SLE disease, as adjudicated by the Central Adjudication Committee, defined as:

(a) SLEDAI-2K activity of: (i) ≥ 6 points with at least 4 points (≥ 4 points) coming from the following clinical components ('Clinical' SLEDAI-2K score): arthritis, myositis, rash, alopecia, mucosal ulcers, pleurisy, pericarditis, or vasculitis and excluding points attributed to a fever, SLE headache, and organic brain syndrome (ii) Clinical SLEDAI score of ≥ 4 points verified at Day 1 (b) BILAG-2004 activity of: (i) ≥ 1 BILAG A score; or (ii) ≥ 2 BILAG B scores (c) PGA score ≥ 1.0 on a 0 to 3 VAS

• Participant should meet all of following tuberculosis (TB) criteria:

A. No signs or symptoms of active TB B. No medical history or past physical examinations suggestive of active TB C. No recent contact with a person with active TB or if there has been such contact, referral to a TB specialist for evaluation and initiation of treatment for latent TB, if warranted, prior to the first administration of study intervention in accordance with local SoC D. No history of latent TB without documented completion of treatment prior to initial screening visit

• Female participants of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at randomization.
• Female participants of childbearing and male participants must adhere to the contraception methods.

Критерии исключения

• Known diagnosis of an IFN-mediated autoinflammatory interferonopathy.
• History of, or current diagnosis of, clinically significant non-SLE-related vasculitides.
• In participants aged 11 years and above: history or evidence of suicidal ideation.
• History of any non-SLE disease that has required treatment with oral or parenteral corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to signing the ICF.
• Any positive result on screening for human immunodeficiency virus.
• Active hepatitis B surface antigen OR hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody and detectable HCV ribonucleic acid (RNA) or any active or recent case of Herpes Zoster infection.
• Any clinical cytomegalovirus or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF.
• History of severe COVID-19 infection requiring hospitalization, intensive care unit care, or assisted ventilation or any prior COVID-19 infection with unresolved sequelae. Any mild/asymptomatic COVID-19 infection (laboratory confirmed or suspected based on clinical symptoms).
• Prior use of anifrolumab.
• Prior treatment with directly acting cytotoxic B-cell depleting therapeutics (eg, rituximab) < 26 weeks prior to ICF signature.
• Blood transfusion or receipt of blood products except albumin within 4 weeks prior to signing the ICF.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

США · 22 центра

• Research Site — Phoenix
• Research Site — Los Angeles
• Research Site — Washington D.C.
• Research Site — Chicago
• Research Site — Chicago
• Research Site — New Orleans
• Research Site — Bethesda
• Research Site — Saint Paul
• … и ещё 14 центров

Китай · 10 центров

• Research Site — Пекин
• Research Site — Пекин
• Research Site — Пекин
• Research Site — Changchun
• Research Site — Чанша
• Research Site — Нанкин
• Research Site — Шанхай
• Research Site — Сучжоу
• … и ещё 2 центра

Япония · 10 центров

• Research Site — Bunkyō City
• Research Site — Bunkyō City
• Research Site — Chiba
• Research Site — Fuchu-shi
• Research Site — Kawasaki-shi
• Research Site — Kobe
• Research Site — Obu-shi
• Research Site — Shinjuku-ku
• … и ещё 2 центра

Испания · 7 центров

Список центров уточняется — проверьте первичный протокол.

Великобритания · 7 центров

Список центров уточняется — проверьте первичный протокол.

Бразилия · 5 центров

• Research Site — Belo Horizonte
• Research Site — Porto Alegre
• Research Site — Ribeirão Preto
• Research Site — São Paulo
• Research Site — São Paulo

Франция · 5 центров

• Research Site — Bordeaux
• Research Site — Bron
• Research Site — Le Kremlin-Bicêtre
• Research Site — Lille
• Research Site — Toulouse

Италия · 5 центров

• Research Site — Genova
• Research Site — Milan
• Research Site — Milan
• Research Site — Padova
• Research Site — Roma

Мексика · 5 центров

• Research Site — Atizapán de Zaragoza
• Research Site — Guadalajara
• Research Site — Mérida
• Research Site — México
• Research Site — Monterrey

Аргентина · 4 центра

• Research Site — Buenos Aires
• Research Site — Córdoba
• Research Site — Rosario
• Research Site — San Miguel de Tucumán

Turkey (Türkiye) · 4 центра

Список центров уточняется — проверьте первичный протокол.

Канада · 3 центра

• Research Site — Calgary
• Research Site — Vancouver
• Research Site — Toronto

Германия · 3 центра

• Research Site — Berlin
• Research Site — Freiburg im Breisgau
• Research Site — Sankt Augustin

Польша · 3 центра

• Research Site — Lodź
• Research Site — Warsaw
• Research Site — Wroclaw

Португалия · 3 центра

• Research Site — Lisbon
• Research Site — Lisbon
• Research Site — Porto

Колумбия · 2 центра

• Research Site — Barranquilla
• Research Site — Medellín

ЮАР · 1 центр

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT05835310 · D3461C00030 · 2022-502289-25-00

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗